u think 3% dividend makes for 15% loss of capital? stock has gone down from 114 to 96 despite strong economy and low fuel
its very old call . Jan2014...with $70..
celgene has come long way..9/10 analayst still recommend v. strong buy...
Yes, short for day or two....MM will take to $500..
it is best among the best sectors.. if u want to short go with speculatives that went up with rising tide..don;t short CELG.BIIB,GILD...
all short term money is out...that got in Jan-Feb when BIIB was at this level.
I feel BIIB will stagnate between 370-400 till next earnings...
...very shareholder friendly mgmt. $7 billion cash on books and increasing, no debt
goes to 135
any opinion.. i am already long cost avg. around 280
...got too much on downside.. actually this is good for long term health of stock..to shake out short term traders...as long as fundamentals intact..which i believe they are
We keep our 12-month target at $146 on a below peers 1.1X PE-to-growth ratio based on our 2015
EPS estimate. Q1 EPS of $1.07 vs. $0.83 is $0.03 ahead of our estimate. However, sales growth,
including 2% adverse forex impact, of 20.2% was below our 22% growth forecast. Revlimid sales
rose 17%, Abraxane rose 21%, and Pomalyst/Imnovie rose 46%, but Vidaza sales fell 3% on
generic competition. We remain encouraged by the growth of Revlimid and believe further label
expansion will drive continued demand and we see Abraxane sales reaching $1B this year.
highly overpriced, write to the Alexion investor relations....they paid premium for pipeline..but that's if and buts'
...or something we don't know/.